氯化二氢1-苯甲基-4,5--1-[3-[(1-羰基十二基)氨基]丙基]-2-十一烷基-1H-咪唑正离子

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 氯化二氢1-苯甲基-4,5--1-[3-[(1-羰基十二基)氨基]丙基]-2-十一烷基-1H-咪唑正离子
• 中文别名: 喹洛雷二盐酸盐
• 英文名称: (5aR,9aR)-6-propyl-5a,7,8,9,9a,10-hexahydro-5H-pyrido[2,3-g]quinazolin-2-amine;hydron;dichloride
• 化学式: C14H24Cl2N4
• 分子量: 319.3
• InChiKey: WDEMLQIGYYLRRX-OWVUFADGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.49
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  55
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  喹洛雷 生成 氯化二氢1-苯甲基-4,5--1-[3-[(1-羰基十二基)氨基]丙基]-2-十一烷基-1H-咪唑正离子
  参考文献：
  名称：

  Trans-(

  摘要：

  Trans-(.+-.)-2-氨基或取代氨基-4-可取代的6-较低烷基或丙烯基-5,5a,-6,7,8,9,9a,10-八氢吡咯并[4,5-g]喹啉，对应的trans-(-)-立体异构体及其盐，用于治疗焦虑、帕金森氏症、性功能障碍、抑郁症、高血压和升高的催乳素水平，以及用于合成的中间体。

  公开号：

  US04501890A1

文献信息

• Pyrimido(4,5-g)quinolines, process for their preparation, and pharmaceutical compositions containing them
  申请人：ELI LILLY AND COMPANY

  公开号：EP0139393A2

  公开（公告）日：1985-05-02

  Trans-(±)-2-Amino (or substituted amino)-4-(permissibly-substituted)-6-C1-C3 alkyl (or allyl)-5,5a,-6,7,8,9,9a,10-octahydropyrimido[4,5-g]quinolines, the corresponding trans-(-) and trans-(+)-stereoisomers and salts thereof, useful in treating Parkinson's Syndrome, sexual dysfunction, depression, hypertension, and prolactin related diseases, and intermediates useful for the synthesis thereof, are disclosed. The products are prepared by condensing an appropriate ketone with the appropriately substituted guanidine.

  本发明涉及转型-(±)-2-氨基(或取代氨基)-4-(可取代基)-6-C1-C3烷基(或烯丙基)-5,5a,-6,7,8,9,9a,10-八氢嘧啶[4,5-g]喹啉，相应的转型-(-)和转型-(+)-立体异构体及其盐，用于治疗帕金森综合症、性功能障碍、抑郁症、高血压和催乳素相关疾病，以及用于其合成的中间体。所述产品通过将适当的酮与适当取代的胍缩合制备而成。
• Treatment of sexual dysfunction
  申请人：——

  公开号：US20020169101A1

  公开（公告）日：2002-11-14

  Bombesin receptor antagonists have been found to be useful in the treatment of sexual dysfunction in both males and females. They may be selective BB1 antagonists or mixed BB1/BB2 antagonists. Combinations are disclosed of bombesin receptor antagonists with a range of other active compounds, for example PDE5 inhibitors, NEP inhibitors and lasofoxifene.

  Bombesin受体拮抗剂已被发现在男性和女性的性功能障碍治疗中非常有用。它们可以是选择性BB1拮抗剂或混合BB1 / BB2拮抗剂。揭示了与一系列其他活性化合物的Bombesin受体拮抗剂的组合，例如PDE5抑制剂，NEP抑制剂和lasofoxifene。
• Bombesin receptor antagonists
  申请人：——

  公开号：US20040110768A1

  公开（公告）日：2004-06-10

  Bombesin receptor antagonists are provided which are compounds of formula (I) or pharmaceutically acceptable salts thereof: 1 wherein j, k, l, m, n, q, r, Ar, Ar 1 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and X are as defined in the description. The compounds of the invention have an affinity for the BB 1 receptor and some of them also have affinity for the BB 2 receptor. Accordingly they may be useful for the diagnosis, prevention, or treatment of male and female sexual dysfunction. They can also be used in the diagnosis, prevention or treatment of anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders or pruritus.

  提供了化合物(I)或其药学上可接受的盐，其是Bombesin受体拮抗剂：1其中j、k、l、m、n、q、r、Ar、Ar1、R1、R2、R3、R4、R5、R6和X如说明书中所定义的。本发明的化合物具有对BB1受体的亲和力，其中一些化合物还具有对BB2受体的亲和力。因此，它们可能对男性和女性的性功能障碍的诊断、预防或治疗有用。它们还可用于焦虑和恐慌障碍、社交恐惧症、抑郁症、精神病、睡眠障碍、记忆障碍、肺动脉高压、肺修复和肺发育障碍、包括前列腺癌和胰腺癌在内的癌症、肝卟啉症、胃肠分泌紊乱、包括结肠炎、克罗恩病和炎症性肠病在内的胃肠疾病、呕吐、厌食、疼痛、季节性情感障碍、进食障碍或瘙痒的诊断、预防或治疗中使用。
• Methods for the detection, treatment, and prevention of neurodegeneration
  申请人：——

  公开号：US20030017479A1

  公开（公告）日：2003-01-23

  In general, the invention provides methods for identifying genes involved in neurodegeneration and therapeutics for treating animals with a neurodegenerative disease. Methods and kits for the detection of compounds which enhance neuroprotection and diagnostic kits for the detection of neurodegenerative diseases are also a part of the invention.

  总之，本发明提供了鉴定参与神经退行性变的基因的方法和治疗患有神经退行性变疾病的动物的疗法。本发明还包括用于检测可增强神经保护作用的化合物的方法和试剂盒，以及用于检测神经退行性疾病的诊断试剂盒。
• EP0139393B1
  申请人：——

  公开号：EP0139393B1

  公开（公告）日：1991-05-15